Abivax Late-Breaking Abstract Presentation and Live Industry Symposium at the UEG Week Virtual 2021
Principal investigator Prof. Séverine Vermeire, M.D., Ph.D, to present Abivax's late-breaking abstract on ABX464 phase 2b study results in ulcerative colitis (UC)
October 4, 2021, at 10:42-10:54 am CEST
Abivax will also be hosting a Live Industry Symposium on ABX464's potential to address medical needs in UC, presentations will be given by key opinion leaders Prof. Bruce Sands, M.D., M.S. and Prof. William Sandborn, M.D.
October 4, 2021, at 1:00-2:00 pm CEST
PARIS, FRANCE / ACCESSWIRE / September 28, 2021 / Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, would like to invite you to attend the Abivax late-breaking abstract presentation as well as the Abivax Live Industry Symposium at the UEG Week Virtual 2021 (registered UEG participants only). The UEG Week 2021 takes place virtually from October 3-5, 2021, and is one of the world's leading congresses focused on gastrointestinal diseases, such as Inflammatory Bowel Diseases (IBD).
Abivax late-breaking abstract presentation
Abivax's late-breaking abstract on its ABX464 phase 2b clinical data in UC has been accepted for this year's UEG Week and will be presented by Prof. Séverine Vermeire, M.D., Ph.D, the principal investigator of the study. Participants will have the opportunity to ask questions after the presentation.
New data on Abivax's phase 2b maintenance results, including the first 101 patients who completed 48 weeks of daily treatment with ABX464, will be made public for the first time during the oral presentation.
Late-breaking Abstracts III: Clinical trials in IBD
Oral ABX464 QD is efficacious and safe during phase 2b induction and maintenance treatment of ulcerative colitis
October 4, 2021 - at 10:42-10:54 am CEST (4:42-5:54 am EST)
Prof. Séverine Vermeire, M.D., Ph.D., Head of the IBD Center at the University Hospitals Leuven, Belgium, and principal investigator of the ABX464 phase 2a and phase 2b clinical studies in UC
Abivax Live Industry Symposium
The symposium will be chaired by Prof. Bruce Sands, M.D., M.S., of the Icahn School of Medicine at Mount Sinai, New York City, NY, USA. The focus of the symposium will be on the continued need for novel drugs in IBD, the clinical data from the phase 2b induction and maintenance studies with ABX464 in UC and the novel mechanism of action of ABX464.
Following the presentations, participants will have the opportunity to ask questions during the live Q&A session.
ABX464, a novel anti-inflammatory drug-candidate for the treatment of ulcerative colitis
October 4, 2021 - 1:00-2:00 pm CEST (7:00-8:00 am EST)
- The continued need to develop novel drugs for ulcerative colitis
Prof. William Sandborn, M.D.
University of California San Diego School of Medicine and Co-Founder and Chief Medical Officer at Shoreline Biosciences, CA, USA
- ABX464 novel mechanism of action: Upregulation of the anti-inflammatory microRNA miR-124
Didier Scherrer, Ph.D.
Vice-President R&D, Abivax, France
- Safety and efficacy of ABX464 in a phase 2b study in ulcerative colitis
Prof. Bruce Sands, M.D., M.S.
Dr. Burrill B. Crohn Professor of Medicine at the Icahn School of Medicine at Mount Sinai, New York City, NY, USA
- Live Q&A session
Registered UEG Week participants can follow the live symposium and view the subsequently provided on-demand replay under the following link: https://virtualweek.ueg.eu/symposium/is-10
About Abivax (www.abivax.com)
Abivax, a clinical stage biotechnology company, is developing novel therapies that modulate the physiological inflammation and immunological pathways to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax is listed on Euronext compartment B (ISIN: FR0012333284 - Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe chronic inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at www.abivax.com. Follow us on Twitter @ABIVAX_.
+33 6 24 50 69 63
+44 7413 825310
Press Relations & Investors Europe
MC Services AG
+49 211 529 252 22
Public Relations France
+33 6 21 10 49 24
Public Relations France
Thomas Roborel de Climens
+33 6 14 50 15 84
Public Relations USA
Rooney Partners LLC
+1 646 770 8858
View source version on accesswire.com: